Full Spectrum Cancer Screening

---

AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, CTNNA1, DICER1, EGFR, EPCAM, FH, FLCN, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL

Our Multi-Cancer screening evaluates genes linked to an increased risk of cancers that typically develop in adults and are not associated with specific syndromes. This test covers a range of organ systems, including but not limited to the breasts, reproductive organs (ovarian, uterine/endometrial), gastrointestinal tract (colorectal, gastric, pancreatic), endocrine system (thyroid, parathyroid, pituitary, adrenal glands), urinary system (renal/urinary tract, prostate), skin (melanoma, basal cell carcinoma), and the brain/nervous system. Due to the genetic complexity of these cancers, relying solely on physical symptoms to identify a cause can be challenging. Additionally, some of the genes analyzed may be linked to other unrelated conditions, which are not part of this screening. By detecting germline mutations, our test can support a clinical cancer diagnosis, offer insights into the likely course and outcome of the disease, enable earlier symptom identification, guide decisions about family planning and genetic counseling, and identify eligibility for clinical research studies. This test is not suitable for identifying somatic mutations in tumor samples.

1. APC-associated      polyposis conditions
2. Ataxia      telangiectasia (A-T)
3. BAP1 tumor      predisposition syndrome
4. Basal      cell nevus syndrome, also known as Gorlin syndrome
5. Birt-Hogg-Dubé      (BHD) syndrome
6. Bloom      syndrome
7. Carney      complex
8. CDC73-related      conditions (hyperparathyroidism-jaw tumor syndrome (HPT-JT),      parathyroid carcinoma, and familial isolated hyperparathyroidism (FIHP)
9. CDK4-related      cutaneous melanoma
10. Coffin-Siris      syndrome
11. Constitutional      mismatch repair deficiency (CMMR-D)
12. DICER1-related      pleuropulmonary blastoma familial tumor predisposition syndrome
13. EGFR-related      conditions
14. Familial GIST, familial mastocytosis
15. Familial      isolated pituitary adenoma
16. Familial      meningioma
17. Familial      neuroblastoma
18. Fanconi      anemia
19. FH      tumor predisposition syndrome
20. GIST-plus      syndrome
21. Hereditary      breast and gynecologic cancers
22. Hereditary      breast and ovarian cancer syndrome (HBOC)
23. Hereditary      diffuse gastric cancer syndrome
24. Hereditary      mixed polyposis syndrome
25. Hereditary      paraganglioma-pheochromocytoma syndrome
26. Hereditary      retinoblastoma
27. HOXB13-related      predisposition to prostate cancer
28. Juvenile      polyposis syndrome (JPS)
29. Li-Fraumeni      syndrome
30. Lynch      syndrome
31. MBD4-associated      neoplasia syndrome (MANS)
32. Melanoma-pancreatic      cancer syndrome and melanoma-neural system tumor syndrome
33. MET-related      conditions
34. MITF-related      conditions
35. MSH3-associated      polyposis
36. Multiple      endocrine neoplasia type 1 (MEN1)
37. Multiple      endocrine neoplasia type 2 (MEN2)
38. Multiple      endocrine neoplasia type 4 (MEN4)
39. MUTYH-associated      polyposis (MAP)
40. NF1-related      conditions
41. Noonan      spectrum disorders
42. NTHL1-associated      polyposis
43. Oligodontia-colorectal      cancer syndrome
44. Peutz-Jeghers      syndrome
45. Polymerase      proofreading–associated polyposis (PPAP)
46. POT1 tumor      predisposition syndrome
47. PTEN hamartoma      tumor syndrome
48. Rhabdoid      tumor predisposition syndrome
49. Schwannomatosis
50. Small      cell carcinoma of the ovary, hypercalcemic type
51. Tuberous      sclerosis complex
52. von      Hippel-Lindau syndrome